



the heart of recovery

**FOR IMMEDIATE RELEASE**

Contact: Chelsey Bonvechio

Marketing Assistant

(856) 455-7575 ext. 1108

[cbonvechio@seabrook.org](mailto:cbonvechio@seabrook.org)

**SEABROOK® EXPANDS DETOX PROGRAM**

**Bridgeton, NJ (May 8, 2018)** – Seabrook addiction treatment center has applied to the State of New Jersey, DHS, Office of Licensing, to add an additional 13 licensed residential detox beds to its already existing 37 licensed beds at their Bridgeton, NJ location. This expansion will address head on the demand for treatment services for those addicted to opioids and other substances.

The new capacity of 50 licensed beds will be housed in two separate buildings on the Bridgeton main campus. The Seabrook medical building will maintain its current capacity of 29 beds. The additional 21 beds will be located in the 42,000 sq. ft. Recovery Center building. The program will offer gender separate accommodations, in both private and semi-private rooms, addressing withdrawal management from all substances including alcohol, benzodiazepines, like Xanax and valium and barbiturates. Seabrook will expand its capacity to manage the withdrawal of patients dependent on opioids such as heroin and prescription pain relievers, morphine, codeine and semi-synthetic opioids like oxycodone and hydrocodone. Lengths of stay will range from four days to 15 days, depending on the severity of the withdrawal symptoms. Following completion of the detox program, patients may enter into the Seabrook residential rehab program or outpatient programs, return home or transition to a sober living home and enroll in a local outpatient program. Patients are not required to enroll in Seabrook aftercare programs.

Seabrook detox programs are designed to meet the definition of the *American Society of Addiction Medicine Level 3.7*. Defined as medically monitored intensive inpatient services, providing 24-hour nursing care, physician and other medical and clinical practitioners, available to address the biomedical, emotional, behavioral and cognitive problems. Patients at this level of care require medication because their symptoms are so severe. Laboratory testing is used to assess recent substance use. This will include urine alcohol and drug screen, testing for liver enzymes, serum bilirubin, serum creatinine, as well as tests for hepatitis B and C and HIV.

Level 3 also encompasses residential services described as co-occurring capable, which are staffed by designated addiction treatment, mental health and general medical personnel who provide a range of services.

A proven and effective response to both opioid use disorder as well as alcohol-related disorders is Medication-Assisted Treatment (MAT). A common misconception associated with MAT is that it substitutes one drug for another. Instead these medications relieve withdrawal symptoms and psychological cravings that cause chemical imbalances in the body. It is the use of medications, in combination with behavioral therapies, to provide a whole-patient approach. Individuals receiving MAT often demonstrate dramatic improvement in addiction related behaviors and psychosocial functioning<sup>1</sup>. Seabrook administers the medication buprenorphine for both short-term stabilization as well as long-term maintenance for those diagnosed with opioid use disorder. In some instances, methadone may be a more effective medication. Acamprosate calcium is a medication used specifically to reduce the physical and emotional distress that can occur in the weeks and months after alcohol consumption has stopped. Naltrexone is a medication used to treat both opioid and alcohol use disorders. It blocks the euphoric effects and the feelings of intoxication and sedation, as well as reducing cravings. Extended-release injectable naltrexone (Vivitrol®) is a long acting formulation administered as a once-monthly injection.

To assist in the increased demand and volume, Seabrook is expanding both the care management and transportation departments. For the convenience of patients and their families, transportation is offered for day, evening and weekend admissions, typically within a 4-hour radius. Care managers begin the discharge planning on the first day of admission. Early discharge planning assures a smooth and successful transfer and discharge process.

Seabrook Medical Director, Dr. Joseph N. Ranieri, DO, FASAM, FAAFP, Diplomat - ABAM, supervises and leads the medical and clinical teams at Seabrook. He is assisted by Director of Medical Services, William Bruck, MSN, APN, FNP-BC, PMP, along with a team of psychiatric nurse practitioners, physician assistants and more than 20 registered nurses.

For more information please visit [www.Seabrook.org](http://www.Seabrook.org), or call the 24-hour help line at [1-800-761-7575](tel:1-800-761-7575).

####

Seabrook is a nonprofit, recognized, CARF-accredited addiction and co-occurring mental health treatment center, with treatment locations in Bridgeton, NJ, Cherry Hill, NJ, Northfield, NJ, Morristown, NJ and Shrewsbury, NJ. Founded by Jerry and Peg Diehl in 1974, Seabrook has been helping families find the courage to recover from addiction and co-occurring mental health for over 44 years. For more information on Seabrook, visit the company website at [www.Seabrook.org](http://www.Seabrook.org).

---

<sup>1</sup> "Medication-Assisted Treatment of Opioid Use Disorder" SAMHSA publication